Euronext today announced the results of the annual review for the BEL 20®, BEL Mid® and BEL Small® indices, which will take place after markets close on Friday 18 March 2022 and be effective from Monday 21 March 2022.
Results of the annual review:
|
Inclusion of: |
Exclusion of: |
|
D’Ieteren Group |
Melexis |
|
VGP |
Telenet Group |
BEL Mid®
|
Inclusion of: |
Exclusion of: |
|
Azelis Group |
Biocartis |
|
Melexis |
D’Ieteren Group |
|
Telenet Group |
VGP |
BEL Small®
|
Inclusion of: |
Exclusion of: |
|
Biocartis |
/ |
|
Onward Medical |
|
The Independent Supervisor retains the right to change the published selection, for instance in the case of a removal due to a takeover, until the publication of the final data after close of Wednesday 16 March 2022.
All events happening after that date will not lead to a replacement of the selected company that possibly needs to be removed from the final selection.
Review BEL® Family
The BEL® Family is reviewed quarterly (March, June, September, December). The full annual review of the BEL® 20 is in March. The June, September and December reviews serve to facilitate inclusion of highly ranked non-constituents (for example recently listed companies) and to replace removed constituents.
Next BEL Steering Committee meeting: Wednesday 8 June 2022.
